Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Expensify Inc (EXFY) vs Cassava Sciences Inc (FLNA) Price & Performance

Expensify IncTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Expensify Inc vs Cassava Sciences Inc — how do they compare? Expensify Inc trades at $2.23 (market cap $209.73M), while Cassava Sciences Inc trades at $0.93 (market cap $47.75M). The key difference: Expensify Inc is far larger — about 4.4× Cassava Sciences Inc's market cap, and Expensify Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

EXFYFLNA
Market Cap
$209.73M$47.75M
Sector
TechnologyHealth
52-Week High
$2.69$4.64
52-Week Low
$0.75$0.87
Enterprise Value
$149.35M-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Expensify Inc

EXFY trades at $2.27, down 8.1% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $33.9 million with improved profitability and cash flow, beating EPS expectations. Recent news highlights expansion into Europe and AI product enhancements. Valuation ratios show a high P/E of 258.82 but reasonable P/S of 1.56, while profitability metrics remain negative.

Outlook is cautiously optimistic due to earnings beats and strategic growth initiatives, but risks include persistent net losses and competitive pressures. Analyst sentiment is mixed with a Buy consensus but requires monitoring of margin improvements.

Cassava Sciences Inc

FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.

The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Expensify Inc

Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.

Read more on EXFY

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA